Study of Sorafenib/Cetuximab in Head and Neck Cancer
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
In this Phase I B/II trial, we seek to determine the safety and efficacy of sorafenib with
standard dose cetuximab in the treatment of patients with Recurrent and /or Metastatic
Squamous Cell Carcinoma of the Head and Neck (SCCHN).